Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Boehringer's zongertinib and Bayer's BAY 2927088 are in phase 3 testing for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations, and the WCLC congress gave an opportunity to ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

BH-30643 is an OMNI-EGFR inhibitor that targets classical, atypical, and compound EGFR mutations and acquired resistance mutations in HER2.

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

and specifically in the HER2-positive breast cancer brain metastasis, we observed that the presence of PIK3CA mutations, in fact, were linked to a worse prognosis. So a worse overall survival from ...